CAS No. 1456803-37-4, (3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidine-3-aminium 4-nitrobenzoate

As an oral calcitonin gene-related peptide (CGRP) receptor antagonist, Ubrogepant offers fast-acting, effective relief for acute migraines without the typical adverse effects of triptans. This novel approach paves the way for a new era in migraine management, providing patients with a much-needed alternative. By incorporating Ubrogepant into your pharmaceutical portfolio, you can make a significant impact on improving the lives of migraine sufferers and advance neurological care.

Stepping up in producing advanced pharmaceutical solutions, Unibest is now offering CAS RN 1456803-37-4, a salient component in the synthesis process of Ubrogepant. Developed with utmost precision, our top-tier compound boosts the drug production process, facilitating a faster path to market for pharmaceutical innovators.

The compound CAS RN 1456803-37-4, essentially the nitrobenzoic acid form of the other half of the Ubrogepant building block, comprises Alanine derivatives as its starting materials.

Our synthesis route incorporates the use of the transaminase ATA-426, a step that is vital to the overall production. As the name implies, this enzyme imparts important nitrogen atoms to the overall chemical structure - a step that significantly contributes to the final form and potency of Ubrogepant.

As a high-value supplier of crucial pharmaceutical intermediates, Unibest ensures robust supply, impeccable quality, and dependable technical support for the distinctive compound CAS RN 1456803-37-4. Our dedication to aiding pharmaceutical industry partners continuously fuels our efforts to contribute to better, healthier lives.